JP5497435B2 - 多層口腔内崩壊錠剤 - Google Patents

多層口腔内崩壊錠剤 Download PDF

Info

Publication number
JP5497435B2
JP5497435B2 JP2009522248A JP2009522248A JP5497435B2 JP 5497435 B2 JP5497435 B2 JP 5497435B2 JP 2009522248 A JP2009522248 A JP 2009522248A JP 2009522248 A JP2009522248 A JP 2009522248A JP 5497435 B2 JP5497435 B2 JP 5497435B2
Authority
JP
Japan
Prior art keywords
opioid
orally disintegrating
multilayer tablet
tablet according
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009522248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545561A5 (https=
JP2009545561A (ja
Inventor
ウーリー パスカル
アリー カトリーヌ
オアラウ ディディエ
Original Assignee
エチファーム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エチファーム filed Critical エチファーム
Publication of JP2009545561A publication Critical patent/JP2009545561A/ja
Publication of JP2009545561A5 publication Critical patent/JP2009545561A5/ja
Application granted granted Critical
Publication of JP5497435B2 publication Critical patent/JP5497435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2009522248A 2006-08-04 2007-07-31 多層口腔内崩壊錠剤 Active JP5497435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82145506P 2006-08-04 2006-08-04
US60/821,455 2006-08-04
PCT/EP2007/057913 WO2008015221A2 (en) 2006-08-04 2007-07-31 Multilayer orally disintegrating tablet

Publications (3)

Publication Number Publication Date
JP2009545561A JP2009545561A (ja) 2009-12-24
JP2009545561A5 JP2009545561A5 (https=) 2013-03-14
JP5497435B2 true JP5497435B2 (ja) 2014-05-21

Family

ID=38997507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522248A Active JP5497435B2 (ja) 2006-08-04 2007-07-31 多層口腔内崩壊錠剤

Country Status (12)

Country Link
US (1) US8603525B2 (https=)
JP (1) JP5497435B2 (https=)
KR (1) KR101408315B1 (https=)
CN (1) CN101563069B (https=)
AT (1) ATE462416T1 (https=)
AU (1) AU2007280471B2 (https=)
CA (1) CA2659523C (https=)
DE (1) DE602007005653D1 (https=)
DK (1) DK2046300T3 (https=)
ES (1) ES2343595T3 (https=)
PT (1) PT2046300E (https=)
WO (1) WO2008015221A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001294A (es) * 2006-08-04 2009-05-21 Ethypharm Sa Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
AU2008318851B2 (en) 2007-10-31 2014-04-17 Mcneil-Ppc, Inc. Orally disintegrated dosage form
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
DK2328561T3 (en) * 2008-08-19 2016-02-08 Adcock Ingram Intellectual Property Pty Ltd Rate modulated administration of drugs from a three-layered tablet containing tramadol, diclofenac, paracetamol
JP2012521393A (ja) * 2009-03-26 2012-09-13 ロイヤル カレッジ オブ サージェオンズ イン アイルランド 口腔内分散性錠剤
JP5845172B2 (ja) * 2009-05-01 2016-01-20 アデア ファーマスーティカルズ，インコーポレイテッド 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US8597681B2 (en) * 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011087765A2 (en) * 2009-12-22 2011-07-21 Mallinckrodt Inc. Methods of producing stabilized solid pharmaceutical compositions containing morphinans
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
EP2906202A4 (en) * 2012-10-15 2016-04-27 Isa Odidi ORAL DRUG RELIEF FORMULATIONS
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015105992A1 (en) 2014-01-10 2015-07-16 Mcneil-Ppc, Inc. Process for making tablet using radiofrequency and lossy coated particles
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN104311447B (zh) * 2014-10-09 2016-09-28 吉林省吴太感康药业有限公司 对乙酰氨基酚新晶型、其制备方法及复方氨酚烷胺制剂
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
BR112017009521A2 (pt) 2014-11-11 2017-12-19 Shionogi & Co comprimido de múltiplas camadas que contém um fármaco instável à luz
JP6696994B2 (ja) 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
WO2017017679A1 (en) * 2015-07-29 2017-02-02 Dexcel Pharma Technologies Ltd. Compositions comprising atorvastatin or a pharmaceutically acceptable salt thereof
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US11096895B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet suitable for active pharmaceutical ingredients
US11052047B2 (en) * 2018-05-17 2021-07-06 Fertin Pharma A/S Oral tablet suitable for fast release of active pharmaceutical ingredients
US11096896B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
BR112020022379A2 (pt) * 2018-05-17 2021-02-02 Fertin Pharma A/S goma de mascar em comprimidos adequada para ingredientes farmacêuticos ativos
US11096894B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
US20190350858A1 (en) * 2018-05-17 2019-11-21 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the gastrointestinal tract
US11090263B2 (en) * 2018-05-22 2021-08-17 Fertin Pharma A/S Tableted chewing gum suitable for active pharmaceutical ingredients
US11058641B2 (en) * 2018-05-17 2021-07-13 Fertin Pharma A/S Oral tablet for taste masking of active ingredients
US11058633B2 (en) * 2018-05-17 2021-07-13 Fertin Pharma A/S Disintegrating oral tablet suitable for active pharmaceutical ingredients
US11135157B2 (en) * 2018-05-17 2021-10-05 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the throat
JP7134048B2 (ja) * 2018-09-28 2022-09-09 ホソカワミクロン株式会社 測定評価装置及びそれによる評価方法
CN109512796A (zh) * 2018-12-26 2019-03-26 甘肃普安制药股份有限公司 一种氨酚羟考酮胶囊填充方法
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
FR3099881B1 (fr) * 2019-08-13 2022-08-26 Ethypharm Sa Comprimé orodispersible d’opioide à faible dosage et son procédé de préparation.
KR20210119906A (ko) * 2020-03-25 2021-10-06 주식회사 삼양홀딩스 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN117179292A (zh) * 2023-09-21 2023-12-08 深圳天基权健康科技集团股份有限公司 一种富硒健脾营养片的制备方法及富硒健脾营养片
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JP3557654B2 (ja) * 1994-08-01 2004-08-25 大正製薬株式会社 安定なマスキング処理顆粒
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
ATE291418T1 (de) 1998-07-28 2005-04-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
AU753476B2 (en) * 1998-11-25 2002-10-17 Cima Labs, Inc. Taste masking rapid release coating system
FR2790387B1 (fr) 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7326387B2 (en) * 2002-05-20 2008-02-05 Theodore A. M. Arts Air decontamination devices
CN1671358A (zh) * 2002-05-31 2005-09-21 阿尔扎公司 用于渗透传递可变剂量的羟考酮的剂型和组合物
DK1894562T3 (da) * 2002-08-15 2011-03-28 Euro Celtique Sa Farmaceutiske sammensætninger omfattende en opioidantagonist
DE10239999A1 (de) * 2002-08-27 2004-03-04 Röhm GmbH & Co. KG Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen
AU2004246837B2 (en) * 2003-06-06 2009-07-16 Ethypharm Orally-dispersible multilayer tablet
MX2009001294A (es) * 2006-08-04 2009-05-21 Ethypharm Sa Granulo y tableta que se desintegra por vía oral que comprende oxicodona.

Also Published As

Publication number Publication date
AU2007280471B2 (en) 2012-10-18
KR101408315B1 (ko) 2014-06-20
AU2007280471A1 (en) 2008-02-07
US8603525B2 (en) 2013-12-10
WO2008015221A2 (en) 2008-02-07
PT2046300E (pt) 2010-07-01
CN101563069A (zh) 2009-10-21
CA2659523A1 (en) 2008-02-07
CA2659523C (en) 2014-01-28
US20090311320A1 (en) 2009-12-17
DK2046300T3 (da) 2010-07-26
ES2343595T3 (es) 2010-08-04
JP2009545561A (ja) 2009-12-24
KR20090038447A (ko) 2009-04-20
CN101563069B (zh) 2012-07-11
DE602007005653D1 (de) 2010-05-12
HK1128881A1 (en) 2009-11-13
ATE462416T1 (de) 2010-04-15
WO2008015221A3 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
JP5497435B2 (ja) 多層口腔内崩壊錠剤
JP5421775B2 (ja) オキシコドンを含む顆粒及び口腔内崩壊錠剤
JP5572616B2 (ja) 口腔内分散性多層錠剤
CN101505732B (zh) 低剂量阿片类镇痛剂舌下片及其制备方法
CN101141951B (zh) 舌下包衣片
MX2007011977A (es) Composiciones farmaceuticas novedosas utiles en el tratamiento del dolor.
JP2006527184A (ja) 口腔内分散性多層錠剤
NZ281236A (en) Tablet (composition) comprising paracetamol (aceta-minophen) and domperidone (5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol -1-yl) propyl]-4-piperidinyl]-1,3-dihydra-2H-benzimidazol-2-one)
CA2761212A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing
CZ301449B6 (cs) Léková forma
US20100092557A1 (en) Dosage Form Comprising Immediate Release Naproxen and Sustained Release Opioid Analgesic
US20100291209A1 (en) Organic compounds
EP2046300B1 (en) Multilayer orally disintegrating tablet
HK1128881B (en) Multilayer orally disintegrating tablet
HK1125857B (en) Granule and orally disintegrating tablet comprising oxycodone
HK1125857A (en) Granule and orally disintegrating tablet comprising oxycodone

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140306

R150 Certificate of patent or registration of utility model

Ref document number: 5497435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250